Viner CV - Search Results

1

Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.

Viner CV, Selby PJ, Zulian GB, Gore ME, Butcher ME, Wootton CM, McElwain TJ. Viner CV, et al. Cancer Chemother Pharmacol. 1990;25(6):449-53. doi: 10.1007/BF00686058. Cancer Chemother Pharmacol. 1990. PMID: 2138064

2

Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.

Mansi J, Ellis E, Viner C, Mundy J, Smith T, Millar J, Milan S, Gore M, Cunningham D. Mansi J, et al. Cancer Chemother Pharmacol. 1992;30(2):149-51. doi: 10.1007/BF00686408. Cancer Chemother Pharmacol. 1992. PMID: 1600595 Clinical Trial.

3

Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.

Forgeson GV, Selby P, Lakhani S, Zulian G, Viner C, Maitland J, McElwain TJ. Forgeson GV, et al. Br J Cancer. 1988 Oct;58(4):469-73. doi: 10.1038/bjc.1988.243. Br J Cancer. 1988. PMID: 3207601 Free PMC article.

4

High-dose melphalan for multiple myeloma: long-term follow-up data.

Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby PJ, et al. Cunningham D, et al. J Clin Oncol. 1994 Apr;12(4):764-8. doi: 10.1200/JCO.1994.12.4.764. J Clin Oncol. 1994. PMID: 8151320

5

Repeat administration of high dose melphalan in relapsed myeloma.

Mansi JL, Cunningham D, Viner C, Ellis E, Meldrum M, Milan S, Gore M. Mansi JL, et al. Br J Cancer. 1993 Nov;68(5):983-7. doi: 10.1038/bjc.1993.466. Br J Cancer. 1993. PMID: 8217614 Free PMC article.

6

High-dose busulfan in patients with myeloma.

Mansi J, da Costa F, Viner C, Judson I, Gore M, Cunningham D. Mansi J, et al. J Clin Oncol. 1992 Oct;10(10):1569-73. doi: 10.1200/JCO.1992.10.10.1569. J Clin Oncol. 1992. PMID: 1403036

7

High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.

Harding M, Selby P, Gore M, Perren T, Treleavan J, Mansi J, Zulian G, Milan S, Meldrum M, Viner C, et al. Harding M, et al. Eur J Cancer. 1992;28A(8-9):1396-400. doi: 10.1016/0959-8049(92)90528-a. Eur J Cancer. 1992. PMID: 1515256

8

A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma.

Jones AL, O'Brien ME, Lorentzos A, Viner C, Hanrahan A, Moore J, Millar JL, Gore ME. Jones AL, et al. Cancer Chemother Pharmacol. 1992;30(1):73-6. doi: 10.1007/BF00686489. Cancer Chemother Pharmacol. 1992. PMID: 1586984 Clinical Trial.

9

Colony stimulating activity in the serum of patients with multiple myeloma is enhanced by interleukin 3: a possible role for interleukin 3 after high dose melphalan and autologous bone marrow transplantation for multiple myeloma.

Millar BC, Bell JB, Montes A, Millar JL, Maitland JA, Treleaven J, Viner C, Gore M, McElwain TJ. Millar BC, et al. Br J Haematol. 1990 Jul;75(3):366-72. doi: 10.1111/j.1365-2141.1990.tb04350.x. Br J Haematol. 1990. PMID: 2201402

10

Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.

Bell JB, Millar BC, Montes-Borinaga A, Joffe JK, Cunningham D, Mansi J, Treleaven J, Viner C, McElwain TJ. Bell JB, et al. Hematol Oncol. 1990 Nov-Dec;8(6):347-53. doi: 10.1002/hon.2900080607. Hematol Oncol. 1990. PMID: 2286358 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters